# OnCo record nct05989542 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05989542/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05989542", "NCT05989542" ;
  schema:name "A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)"@en ;
  schema:alternateName "KUNPENG-2"@en ;
  schema:description "A phase 3 trial of Vebreltinib run by Beijing Pearl Biotechnology Limited Liability Company in non-small-cell lung cancer and small-cell lung cancer, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05989542/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05989542> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2023-10-16" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/met-altered-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/vebreltinib/> ;
  onco:companies <https://onco.cc/companies/beijing-pearl-biotechnology-limited-liability-company/> .